192 related articles for article (PubMed ID: 16640121)
21. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia.
Kern RS; Green MF; Nuechterlein KH; Deng BH
Schizophr Res; 2004 Dec; 72(1):11-9. PubMed ID: 15531403
[TBL] [Abstract][Full Text] [Related]
22. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
[TBL] [Abstract][Full Text] [Related]
23. An industry perspective on the NIMH consensus statement on negative symptoms.
Alphs L
Schizophr Bull; 2006 Apr; 32(2):225-30. PubMed ID: 16469940
[TBL] [Abstract][Full Text] [Related]
24. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
[TBL] [Abstract][Full Text] [Related]
25. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
26. Wayne Fenton: impact on food and drug administration.
Laughren T
Schizophr Bull; 2007 Sep; 33(5):1153. PubMed ID: 17578891
[No Abstract] [Full Text] [Related]
27. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
Kern RS; Nuechterlein KH; Green MF; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Mintz J; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):214-20. PubMed ID: 18172018
[TBL] [Abstract][Full Text] [Related]
28. Wayne Fenton's impact on academic neuroscience.
Geyer MA; Tamminga CA
Schizophr Bull; 2007 Sep; 33(5):1156-9. PubMed ID: 17617663
[TBL] [Abstract][Full Text] [Related]
29. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
30. Program to improve cognitive functioning in patients with schizophrenia: reflections.
Scolnick E
Schizophr Res; 2004 Dec; 72(1):75-7. PubMed ID: 15531409
[TBL] [Abstract][Full Text] [Related]
31. Medicine. What are the right targets for psychopharmacology?
Hyman SE; Fenton WS
Science; 2003 Jan; 299(5605):350-1. PubMed ID: 12532001
[No Abstract] [Full Text] [Related]
32. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.
Green MF; Kern RS; Heaton RK
Schizophr Res; 2004 Dec; 72(1):41-51. PubMed ID: 15531406
[TBL] [Abstract][Full Text] [Related]
33. [Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].
Rodríguez-Jiménez R; Bagney A; Moreno-Ortega M; García-Navarro C; Aparicio AI; López-Antón R; de la Oliva J; Jiménez-Arriero MÁ; Santos JL; Lobo A; Palomo T
Rev Neurol; 2012 Nov; 55(9):549-55. PubMed ID: 23111994
[TBL] [Abstract][Full Text] [Related]
34. Another view of therapy for cognition in schizophrenia.
Carpenter WT; Gold JM
Biol Psychiatry; 2002 Jun; 51(12):969-71. PubMed ID: 12062880
[No Abstract] [Full Text] [Related]
35. Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia.
Takeuchi H; Fervaha G; Remington G
J Clin Psychopharmacol; 2015 Dec; 35(6):728-30. PubMed ID: 26479222
[No Abstract] [Full Text] [Related]
36. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.
Carter CS; Barch DM
Schizophr Bull; 2007 Sep; 33(5):1131-7. PubMed ID: 17630405
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological strategies for enhancing cognition in schizophrenia.
Barch DM
Curr Top Behav Neurosci; 2010; 4():43-96. PubMed ID: 21312397
[TBL] [Abstract][Full Text] [Related]
38. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.
Purdon SE
J Psychiatry Neurosci; 2000 Mar; 25(2):108-16. PubMed ID: 10740984
[No Abstract] [Full Text] [Related]
39. The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.
Rodriguez-Jimenez R; Bagney A; Garcia-Navarro C; Aparicio AI; Lopez-Anton R; Moreno-Ortega M; Jimenez-Arriero MA; Santos JL; Lobo A; Kern RS; Green MF; Nuechterlein KH; Palomo T
Schizophr Res; 2012 Feb; 134(2-3):279-84. PubMed ID: 22192501
[TBL] [Abstract][Full Text] [Related]
40. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness.
Marder SR
J Clin Psychiatry; 2006 Jul; 67(7):e03. PubMed ID: 17107228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
